Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Pain 5Neoplasms 4Chronic Pain 1Cancer Pain 1Agnosia 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Tapentadol × Clear all
NCT00472303 2019-11-04

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Completed
622 enrolled 31 charts

Cancer Pain, Neoplasms, Pain

NCT01264887 2019-11-04

Tapentadol in Chronic Malignant Tumour Related Pain

Grünenthal GmbH

Phase 3 Terminated
31 enrolled 19 charts

Agnosia, Neoplasms, Pain, Chronic Pain

NCT00505414 2019-11-01

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Terminated
136 enrolled 9 charts

Neoplasms, Pain

NCT01165281 2017-07-21

A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

Janssen Research & Development, LLC

Phase 3 Completed
343 enrolled 15 charts

Pain

NCT00805142 2013-07-29

Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants

Janssen Pharmaceutical K.K.

Phase 2 Completed
78 enrolled 16 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡